Tag: Sarcopenia Treatment Market Demand

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Digital Therapeutics Sarcopenia Market Size Outlook: How Fast Will Revenue Grow Through 2030?

The market for digital therapeutics targeting sarcopenia has experienced significant expansion recently, with projections indicating a rise from $1.54 billion in 2025 to $1.78 billion by 2026, reflecting a compound annual growth rate of 16.1%. This historical growth trajectory has been bolstered by several key factors, including the increasing prevalence of an aging global population, heightened awareness concerning the health implications of sarcopenia, a growing trend in the adoption of telehealth services, the increasing acceptance of therapeutic solutions delivered via software, and the initial positive outcomes from clinical trials involving digital interventions.

The digital therapeutics market focused on sarcopenia is poised for swift expansion in the upcoming years, projecting a rise to $3.21 billion by 2030, underpinned by a compound annual growth rate (CAGR) of 15.9%. This anticipated growth over the forecast period stems from several key drivers, including a heightened need for managing chronic conditions from home, the increasing incorporation of AI for personalized therapeutic approaches, broader availability of reimbursement for digital health solutions, a greater uptake of remote patient monitoring technologies, and a pronounced emphasis on proactive measures for muscle health. During this same forecast period, significant trends are expected to emerge, such as the wider adoption of individualized digital therapy plans, increased utilization of wearable devices for muscle monitoring, a greater deployment of remote physiotherapy services, the expansion of data-informed strategies for sarcopenia management, and a reinforced focus on engaging patients and ensuring they adhere to their treatment regimens.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27278&type=smp

Digital Therapeutics Sarcopenia Market Growth Momentum: Which Factors Are Influencing Demand?

The increasing incidence of co-occurring health issues is anticipated to be a primary catalyst for the expansion of the digital therapeutics market focused on sarcopenia. These co-occurring conditions, known as comorbidities, involve the simultaneous presence of multiple diseases within one person. Factors such as an aging global population contribute significantly to this rise, as older age groups are more susceptible to developing several chronic ailments due to diminished bodily functions and prolonged exposure to various health hazards. Digital therapeutic solutions designed for sarcopenia offer a valuable approach to mitigating comorbidities, particularly obesity, by encouraging consistent exercise and muscle enhancement activities, thereby aiding metabolic function and curbing excess body fat. Illustrating this trend, by 2035, an estimated 79% of adults grappling with being overweight or obese will reside in lower and middle-income countries, with the global adult population affected by obesity projected to reach 1.53 billion, as reported by the World Obesity Federation in March 2024. Consequently, the growing burden of comorbidities plays a crucial role in fueling the digital therapeutics sarcopenia market’s advancement.

Digital Therapeutics Sarcopenia Market Segmentation Trends And Revenue Drivers

The digital therapeutics sarcopenia market covered in this report is segmented –

1) By Product: Software, Devices, Services

2) By Distribution Channel: Online Platforms, Direct-To-Consumer Digital Channels, Other Distribution Channels

3) By Application: Muscle Strengthening, Physical Activity Monitoring, Nutrition Management, Other Applications

4) By End User: Hospitals And Clinics, Homecare Settings, Rehabilitation Centers, Other End Users

Subsegments:

1) By Software: Mobile Applications, Web-Based Platforms, AI-Powered Monitoring Tools, Exercise And Rehabilitation Programs, Nutritional Guidance Software

2) By Devices: Wearable Fitness Trackers, Smart Scales, Connected Resistance Bands, Electromyography (EMG) Devices, Muscle Strength Assessment Tools

3) By Services: Remote Patient Monitoring Services, Virtual Physiotherapy Sessions, Teleconsultation Services, Personalized Coaching Services, Data Analytics And Reporting Services

Digital Therapeutics Sarcopenia Market Trends Reshaping Industry Growth

In the digital therapeutics market for sarcopenia, leading entities are prioritizing the creation of sophisticated technologies, including drug discovery platforms, with the aim of formulating more precise treatments, boosting therapeutic outcomes, and expediting the provision of individualized care for the decline in muscle mass associated with aging. Such platforms are instrumental in expediting the identification and development of novel pharmaceuticals through the utilization of cutting-edge instruments and techniques. To illustrate, in April 2025, ProFuse Technology, a biotechnology firm headquartered in Israel, introduced an innovative drug discovery platform designed to mitigate muscle deterioration stemming from GLP-1 based weight-loss medications, the natural aging process (sarcopenia), and cancer-related wasting (cachexia). By employing laboratory-cultivated, exceptionally mature muscle tissues that closely replicate in-vivo muscle, the company facilitates rapid and efficient testing and evaluation of potential drug compounds. This sophisticated platform not only lessens the necessity for animal experimentation but also curtails research expenditures. With a growing demand for therapies that preserve muscle mass, ProFuse is diversifying from its cultivated meat ventures into the biopharmaceutical sector, presenting a pioneering strategy to confront the escalating challenges in maintaining muscle health.

#Digital Therapeutics Sarcopenia Market Industry Leaders: Which Organizations Are Driving Competition?

Major companies operating in the digital therapeutics sarcopenia market are Sword Health Inc., Biofourmis Inc., Hinge Health Inc., Omada Health Inc., Evolv Rehabilitation Technologies Ltd., Click Therapeutics Inc., DarioHealth Corp., WellDoc Inc., Lark Technologies Inc., Kaia Health Software GmbH, Liva Healthcare A/S, Zibrio Inc., Gait Up SA, Noraxon Inc., Mira Rehab Limited, Cometa Srl., Koneksa Health Inc., Physitrack PLC, Kaia Health Inc., XRHealth USA Inc., MedRhythms Inc.

Access The Complete Digital Therapeutics Sarcopenia Market Report:

https://www.thebusinessresearchcompany.com/report/digital-therapeutics-sarcopenia-global-market-report

Digital Therapeutics Sarcopenia Market Geographic Distribution And Regional Opportunities

North Americawas the largest region in the digital therapeutics sarcopenia market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the digital therapeutics sarcopenia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Digital Therapeutics Sarcopenia Market Size Outlook: How Fast Will Revenue Grow Through 2030?

The market for digital therapeutics targeting sarcopenia has experienced significant expansion recently, with projections indicating a rise from $1.54 billion in 2025 to $1.78 billion by 2026, reflecting a compound annual growth rate of 16.1%. This historical growth trajectory has been bolstered by several key factors, including the increasing prevalence of an aging global population, heightened awareness concerning the health implications of sarcopenia, a growing trend in the adoption of telehealth services, the increasing acceptance of therapeutic solutions delivered via software, and the initial positive outcomes from clinical trials involving digital interventions.

The digital therapeutics market focused on sarcopenia is poised for swift expansion in the upcoming years, projecting a rise to $3.21 billion by 2030, underpinned by a compound annual growth rate (CAGR) of 15.9%. This anticipated growth over the forecast period stems from several key drivers, including a heightened need for managing chronic conditions from home, the increasing incorporation of AI for personalized therapeutic approaches, broader availability of reimbursement for digital health solutions, a greater uptake of remote patient monitoring technologies, and a pronounced emphasis on proactive measures for muscle health. During this same forecast period, significant trends are expected to emerge, such as the wider adoption of individualized digital therapy plans, increased utilization of wearable devices for muscle monitoring, a greater deployment of remote physiotherapy services, the expansion of data-informed strategies for sarcopenia management, and a reinforced focus on engaging patients and ensuring they adhere to their treatment regimens.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27278&type=smp

Digital Therapeutics Sarcopenia Market Growth Momentum: Which Factors Are Influencing Demand?

The increasing incidence of co-occurring health issues is anticipated to be a primary catalyst for the expansion of the digital therapeutics market focused on sarcopenia. These co-occurring conditions, known as comorbidities, involve the simultaneous presence of multiple diseases within one person. Factors such as an aging global population contribute significantly to this rise, as older age groups are more susceptible to developing several chronic ailments due to diminished bodily functions and prolonged exposure to various health hazards. Digital therapeutic solutions designed for sarcopenia offer a valuable approach to mitigating comorbidities, particularly obesity, by encouraging consistent exercise and muscle enhancement activities, thereby aiding metabolic function and curbing excess body fat. Illustrating this trend, by 2035, an estimated 79% of adults grappling with being overweight or obese will reside in lower and middle-income countries, with the global adult population affected by obesity projected to reach 1.53 billion, as reported by the World Obesity Federation in March 2024. Consequently, the growing burden of comorbidities plays a crucial role in fueling the digital therapeutics sarcopenia market’s advancement.

Digital Therapeutics Sarcopenia Market Segmentation Trends And Revenue Drivers

The digital therapeutics sarcopenia market covered in this report is segmented –

1) By Product: Software, Devices, Services

2) By Distribution Channel: Online Platforms, Direct-To-Consumer Digital Channels, Other Distribution Channels

3) By Application: Muscle Strengthening, Physical Activity Monitoring, Nutrition Management, Other Applications

4) By End User: Hospitals And Clinics, Homecare Settings, Rehabilitation Centers, Other End Users

Subsegments:

1) By Software: Mobile Applications, Web-Based Platforms, AI-Powered Monitoring Tools, Exercise And Rehabilitation Programs, Nutritional Guidance Software

2) By Devices: Wearable Fitness Trackers, Smart Scales, Connected Resistance Bands, Electromyography (EMG) Devices, Muscle Strength Assessment Tools

3) By Services: Remote Patient Monitoring Services, Virtual Physiotherapy Sessions, Teleconsultation Services, Personalized Coaching Services, Data Analytics And Reporting Services

Digital Therapeutics Sarcopenia Market Trends Reshaping Industry Growth

In the digital therapeutics market for sarcopenia, leading entities are prioritizing the creation of sophisticated technologies, including drug discovery platforms, with the aim of formulating more precise treatments, boosting therapeutic outcomes, and expediting the provision of individualized care for the decline in muscle mass associated with aging. Such platforms are instrumental in expediting the identification and development of novel pharmaceuticals through the utilization of cutting-edge instruments and techniques. To illustrate, in April 2025, ProFuse Technology, a biotechnology firm headquartered in Israel, introduced an innovative drug discovery platform designed to mitigate muscle deterioration stemming from GLP-1 based weight-loss medications, the natural aging process (sarcopenia), and cancer-related wasting (cachexia). By employing laboratory-cultivated, exceptionally mature muscle tissues that closely replicate in-vivo muscle, the company facilitates rapid and efficient testing and evaluation of potential drug compounds. This sophisticated platform not only lessens the necessity for animal experimentation but also curtails research expenditures. With a growing demand for therapies that preserve muscle mass, ProFuse is diversifying from its cultivated meat ventures into the biopharmaceutical sector, presenting a pioneering strategy to confront the escalating challenges in maintaining muscle health.

#Digital Therapeutics Sarcopenia Market Industry Leaders: Which Organizations Are Driving Competition?

Major companies operating in the digital therapeutics sarcopenia market are Sword Health Inc., Biofourmis Inc., Hinge Health Inc., Omada Health Inc., Evolv Rehabilitation Technologies Ltd., Click Therapeutics Inc., DarioHealth Corp., WellDoc Inc., Lark Technologies Inc., Kaia Health Software GmbH, Liva Healthcare A/S, Zibrio Inc., Gait Up SA, Noraxon Inc., Mira Rehab Limited, Cometa Srl., Koneksa Health Inc., Physitrack PLC, Kaia Health Inc., XRHealth USA Inc., MedRhythms Inc.

Access The Complete Digital Therapeutics Sarcopenia Market Report:

https://www.thebusinessresearchcompany.com/report/digital-therapeutics-sarcopenia-global-market-report

Digital Therapeutics Sarcopenia Market Geographic Distribution And Regional Opportunities

North Americawas the largest region in the digital therapeutics sarcopenia market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the digital therapeutics sarcopenia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Digital Therapeutics Sarcopenia Market Size Outlook: How Fast Will Revenue Grow Through 2030?

The market for digital therapeutics targeting sarcopenia has experienced significant expansion recently, with projections indicating a rise from $1.54 billion in 2025 to $1.78 billion by 2026, reflecting a compound annual growth rate of 16.1%. This historical growth trajectory has been bolstered by several key factors, including the increasing prevalence of an aging global population, heightened awareness concerning the health implications of sarcopenia, a growing trend in the adoption of telehealth services, the increasing acceptance of therapeutic solutions delivered via software, and the initial positive outcomes from clinical trials involving digital interventions.

The digital therapeutics market focused on sarcopenia is poised for swift expansion in the upcoming years, projecting a rise to $3.21 billion by 2030, underpinned by a compound annual growth rate (CAGR) of 15.9%. This anticipated growth over the forecast period stems from several key drivers, including a heightened need for managing chronic conditions from home, the increasing incorporation of AI for personalized therapeutic approaches, broader availability of reimbursement for digital health solutions, a greater uptake of remote patient monitoring technologies, and a pronounced emphasis on proactive measures for muscle health. During this same forecast period, significant trends are expected to emerge, such as the wider adoption of individualized digital therapy plans, increased utilization of wearable devices for muscle monitoring, a greater deployment of remote physiotherapy services, the expansion of data-informed strategies for sarcopenia management, and a reinforced focus on engaging patients and ensuring they adhere to their treatment regimens.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27278&type=smp

Digital Therapeutics Sarcopenia Market Growth Momentum: Which Factors Are Influencing Demand?

The increasing incidence of co-occurring health issues is anticipated to be a primary catalyst for the expansion of the digital therapeutics market focused on sarcopenia. These co-occurring conditions, known as comorbidities, involve the simultaneous presence of multiple diseases within one person. Factors such as an aging global population contribute significantly to this rise, as older age groups are more susceptible to developing several chronic ailments due to diminished bodily functions and prolonged exposure to various health hazards. Digital therapeutic solutions designed for sarcopenia offer a valuable approach to mitigating comorbidities, particularly obesity, by encouraging consistent exercise and muscle enhancement activities, thereby aiding metabolic function and curbing excess body fat. Illustrating this trend, by 2035, an estimated 79% of adults grappling with being overweight or obese will reside in lower and middle-income countries, with the global adult population affected by obesity projected to reach 1.53 billion, as reported by the World Obesity Federation in March 2024. Consequently, the growing burden of comorbidities plays a crucial role in fueling the digital therapeutics sarcopenia market’s advancement.

Digital Therapeutics Sarcopenia Market Segmentation Trends And Revenue Drivers

The digital therapeutics sarcopenia market covered in this report is segmented –

1) By Product: Software, Devices, Services

2) By Distribution Channel: Online Platforms, Direct-To-Consumer Digital Channels, Other Distribution Channels

3) By Application: Muscle Strengthening, Physical Activity Monitoring, Nutrition Management, Other Applications

4) By End User: Hospitals And Clinics, Homecare Settings, Rehabilitation Centers, Other End Users

Subsegments:

1) By Software: Mobile Applications, Web-Based Platforms, AI-Powered Monitoring Tools, Exercise And Rehabilitation Programs, Nutritional Guidance Software

2) By Devices: Wearable Fitness Trackers, Smart Scales, Connected Resistance Bands, Electromyography (EMG) Devices, Muscle Strength Assessment Tools

3) By Services: Remote Patient Monitoring Services, Virtual Physiotherapy Sessions, Teleconsultation Services, Personalized Coaching Services, Data Analytics And Reporting Services

Digital Therapeutics Sarcopenia Market Trends Reshaping Industry Growth

In the digital therapeutics market for sarcopenia, leading entities are prioritizing the creation of sophisticated technologies, including drug discovery platforms, with the aim of formulating more precise treatments, boosting therapeutic outcomes, and expediting the provision of individualized care for the decline in muscle mass associated with aging. Such platforms are instrumental in expediting the identification and development of novel pharmaceuticals through the utilization of cutting-edge instruments and techniques. To illustrate, in April 2025, ProFuse Technology, a biotechnology firm headquartered in Israel, introduced an innovative drug discovery platform designed to mitigate muscle deterioration stemming from GLP-1 based weight-loss medications, the natural aging process (sarcopenia), and cancer-related wasting (cachexia). By employing laboratory-cultivated, exceptionally mature muscle tissues that closely replicate in-vivo muscle, the company facilitates rapid and efficient testing and evaluation of potential drug compounds. This sophisticated platform not only lessens the necessity for animal experimentation but also curtails research expenditures. With a growing demand for therapies that preserve muscle mass, ProFuse is diversifying from its cultivated meat ventures into the biopharmaceutical sector, presenting a pioneering strategy to confront the escalating challenges in maintaining muscle health.

#Digital Therapeutics Sarcopenia Market Industry Leaders: Which Organizations Are Driving Competition?

Major companies operating in the digital therapeutics sarcopenia market are Sword Health Inc., Biofourmis Inc., Hinge Health Inc., Omada Health Inc., Evolv Rehabilitation Technologies Ltd., Click Therapeutics Inc., DarioHealth Corp., WellDoc Inc., Lark Technologies Inc., Kaia Health Software GmbH, Liva Healthcare A/S, Zibrio Inc., Gait Up SA, Noraxon Inc., Mira Rehab Limited, Cometa Srl., Koneksa Health Inc., Physitrack PLC, Kaia Health Inc., XRHealth USA Inc., MedRhythms Inc.

Access The Complete Digital Therapeutics Sarcopenia Market Report:

https://www.thebusinessresearchcompany.com/report/digital-therapeutics-sarcopenia-global-market-report

Digital Therapeutics Sarcopenia Market Geographic Distribution And Regional Opportunities

North Americawas the largest region in the digital therapeutics sarcopenia market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the digital therapeutics sarcopenia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Estimated Market Size Of The Digital Therapeutics Sarcopenia Market In 2026, And How Will Its Value Evolve By 2030?

The digital therapeutics sarcopenia market size has seen rapid expansion in recent years. It is anticipated to increase from $1.54 billion in 2025 to $1.78 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 16.1%. The growth observed historically can be ascribed to elements such as the increasing prevalence of an aging population, heightened awareness of health risks linked to sarcopenia, the expansion of telehealth adoption, increasing acceptance of software-based medical therapies, and the early clinical validation of digital interventions.

The digital therapeutics sarcopenia market size is projected to experience substantial expansion in the coming years. This market is anticipated to reach a valuation of $3.21 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 15.9%. This projected growth throughout the forecast period stems from factors such as the heightened demand for home-based care for chronic conditions, the escalating incorporation of AI-powered personalized therapies, broadened reimbursement avenues for digital therapeutics, the expanding uptake of remote patient monitoring, and a reinforced emphasis on solutions for preventive muscle health. Key trends anticipated during this period encompass the wider acceptance of tailored digital therapy programs, the increased utilization of wearable devices for muscle monitoring, the broader implementation of remote physiotherapy platforms, the development of data-informed sarcopenia management strategies, and a stronger commitment to patient involvement and compliance.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/digital-therapeutics-sarcopenia-global-market-report

What Major Factors Are Driving The Digital Therapeutics Sarcopenia Market Forward?

The expanding presence of comorbidities is anticipated to fuel the expansion of the digital therapeutics sarcopenia market. Comorbidities are defined as the concurrent existence of multiple health conditions within a single individual. The increase in comorbidities stems from an aging demographic, as older age raises the probability of developing several chronic ailments due to diminishing physiological functions and extended exposure to various health hazards. Digital therapeutics designed for sarcopenia offer advantages in averting comorbidities, particularly obesity, by fostering consistent physical activity and muscle reinforcement, which aids in enhancing metabolism and minimizing fat accumulation. For example, data from March 2024, provided by the World Obesity Federation, a membership body based in the UK, projects that nearly 79% of adults impacted by overweight and obesity will reside in low- and middle-income nations by 2035, with the total count of obese adults forecast to reach 1.53 billion. Consequently, the increasing incidence of comorbidities is propelling the growth of the digital therapeutics sarcopenia market.

How Are Segments Identified Within The Digital Therapeutics Sarcopenia Market Segment Framework?

The digital therapeutics sarcopenia market covered in this report is segmented –

1) By Product: Software, Devices, Services

2) By Distribution Channel: Online Platforms, Direct-To-Consumer Digital Channels, Other Distribution Channels

3) By Application: Muscle Strengthening, Physical Activity Monitoring, Nutrition Management, Other Applications

4) By End User: Hospitals And Clinics, Homecare Settings, Rehabilitation Centers, Other End Users

Subsegments:

1) By Software: Mobile Applications, Web-Based Platforms, AI-Powered Monitoring Tools, Exercise And Rehabilitation Programs, Nutritional Guidance Software

2) By Devices: Wearable Fitness Trackers, Smart Scales, Connected Resistance Bands, Electromyography (EMG) Devices, Muscle Strength Assessment Tools

3) By Services: Remote Patient Monitoring Services, Virtual Physiotherapy Sessions, Teleconsultation Services, Personalized Coaching Services, Data Analytics And Reporting Services

Which Trends Are Impacting The Progress Of The Digital Therapeutics Sarcopenia Market?

Leading companies in the digital therapeutics sarcopenia market are concentrating on developing sophisticated solutions, such as drug discovery platforms. Their objective is to create more targeted therapies, improve treatment effectiveness, and accelerate the provision of personalized care for age-related muscle loss. A drug discovery platform aids in the quicker and more effective identification and creation of new drugs through advanced tools and methods. For example, in April 2025, ProFuse Technology, an Israel-based biotechnology company, unveiled a new drug discovery platform aimed at preventing muscle loss induced by GLP-1 weight-loss drugs, aging (sarcopenia), and cancer cachexia. By employing lab-grown, highly mature muscle tissues that accurately imitate natural muscle, the company can precisely test and screen drug candidates with enhanced speed and efficiency. This advanced platform reduces the dependence on animal testing and decreases research expenses. As the demand for muscle-preserving therapies rises, ProFuse is broadening its scope beyond cultivated meat into the biopharmaceutical industry, offering a pioneering strategy to address increasingly complex muscle health issues.

Who Are The Companies Competing Within The Digital Therapeutics Sarcopenia Market?

Major companies operating in the digital therapeutics sarcopenia market are Sword Health Inc., Biofourmis Inc., Hinge Health Inc., Omada Health Inc., Evolv Rehabilitation Technologies Ltd., Click Therapeutics Inc., DarioHealth Corp., WellDoc Inc., Lark Technologies Inc., Kaia Health Software GmbH, Liva Healthcare A/S, Zibrio Inc., Gait Up SA, Noraxon Inc., Mira Rehab Limited, Cometa Srl., Koneksa Health Inc., Physitrack PLC, Kaia Health Inc., XRHealth USA Inc., MedRhythms Inc.

Get The Full Digital Therapeutics Sarcopenia Market Report:

https://www.thebusinessresearchcompany.com/report/digital-therapeutics-sarcopenia-global-market-report

Which Region Leads The Digital Therapeutics Sarcopenia Market In Overall Market Size?

North America was the largest region in the digital therapeutics sarcopenia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the digital therapeutics sarcopenia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Digital Therapeutics Sarcopenia Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/digital-therapeutics-sarcopenia-global-market-report

Browse Through More Reports Similar to the Global Digital Therapeutics Sarcopenia Market 2026, By The Business Research Company

Battery Separators Market Report 2026

https://www.thebusinessresearchcompany.com/report/battery-separators-global-market-report

Cutter Stapler Market Report 2026

https://www.thebusinessresearchcompany.com/report/cutter-stapler-global-market-report

Battery Manufacturing Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/battery-manufacturing-equipment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Estimated Market Size Of The Digital Therapeutics Sarcopenia Market In 2026, And How Will Its Value Evolve By 2030?

The digital therapeutics sarcopenia market size has seen rapid expansion in recent years. It is anticipated to increase from $1.54 billion in 2025 to $1.78 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 16.1%. The growth observed historically can be ascribed to elements such as the increasing prevalence of an aging population, heightened awareness of health risks linked to sarcopenia, the expansion of telehealth adoption, increasing acceptance of software-based medical therapies, and the early clinical validation of digital interventions.

The digital therapeutics sarcopenia market size is projected to experience substantial expansion in the coming years. This market is anticipated to reach a valuation of $3.21 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 15.9%. This projected growth throughout the forecast period stems from factors such as the heightened demand for home-based care for chronic conditions, the escalating incorporation of AI-powered personalized therapies, broadened reimbursement avenues for digital therapeutics, the expanding uptake of remote patient monitoring, and a reinforced emphasis on solutions for preventive muscle health. Key trends anticipated during this period encompass the wider acceptance of tailored digital therapy programs, the increased utilization of wearable devices for muscle monitoring, the broader implementation of remote physiotherapy platforms, the development of data-informed sarcopenia management strategies, and a stronger commitment to patient involvement and compliance.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/digital-therapeutics-sarcopenia-global-market-report

What Major Factors Are Driving The Digital Therapeutics Sarcopenia Market Forward?

The expanding presence of comorbidities is anticipated to fuel the expansion of the digital therapeutics sarcopenia market. Comorbidities are defined as the concurrent existence of multiple health conditions within a single individual. The increase in comorbidities stems from an aging demographic, as older age raises the probability of developing several chronic ailments due to diminishing physiological functions and extended exposure to various health hazards. Digital therapeutics designed for sarcopenia offer advantages in averting comorbidities, particularly obesity, by fostering consistent physical activity and muscle reinforcement, which aids in enhancing metabolism and minimizing fat accumulation. For example, data from March 2024, provided by the World Obesity Federation, a membership body based in the UK, projects that nearly 79% of adults impacted by overweight and obesity will reside in low- and middle-income nations by 2035, with the total count of obese adults forecast to reach 1.53 billion. Consequently, the increasing incidence of comorbidities is propelling the growth of the digital therapeutics sarcopenia market.

How Are Segments Identified Within The Digital Therapeutics Sarcopenia Market Segment Framework?

The digital therapeutics sarcopenia market covered in this report is segmented –

1) By Product: Software, Devices, Services

2) By Distribution Channel: Online Platforms, Direct-To-Consumer Digital Channels, Other Distribution Channels

3) By Application: Muscle Strengthening, Physical Activity Monitoring, Nutrition Management, Other Applications

4) By End User: Hospitals And Clinics, Homecare Settings, Rehabilitation Centers, Other End Users

Subsegments:

1) By Software: Mobile Applications, Web-Based Platforms, AI-Powered Monitoring Tools, Exercise And Rehabilitation Programs, Nutritional Guidance Software

2) By Devices: Wearable Fitness Trackers, Smart Scales, Connected Resistance Bands, Electromyography (EMG) Devices, Muscle Strength Assessment Tools

3) By Services: Remote Patient Monitoring Services, Virtual Physiotherapy Sessions, Teleconsultation Services, Personalized Coaching Services, Data Analytics And Reporting Services

Which Trends Are Impacting The Progress Of The Digital Therapeutics Sarcopenia Market?

Leading companies in the digital therapeutics sarcopenia market are concentrating on developing sophisticated solutions, such as drug discovery platforms. Their objective is to create more targeted therapies, improve treatment effectiveness, and accelerate the provision of personalized care for age-related muscle loss. A drug discovery platform aids in the quicker and more effective identification and creation of new drugs through advanced tools and methods. For example, in April 2025, ProFuse Technology, an Israel-based biotechnology company, unveiled a new drug discovery platform aimed at preventing muscle loss induced by GLP-1 weight-loss drugs, aging (sarcopenia), and cancer cachexia. By employing lab-grown, highly mature muscle tissues that accurately imitate natural muscle, the company can precisely test and screen drug candidates with enhanced speed and efficiency. This advanced platform reduces the dependence on animal testing and decreases research expenses. As the demand for muscle-preserving therapies rises, ProFuse is broadening its scope beyond cultivated meat into the biopharmaceutical industry, offering a pioneering strategy to address increasingly complex muscle health issues.

Who Are The Companies Competing Within The Digital Therapeutics Sarcopenia Market?

Major companies operating in the digital therapeutics sarcopenia market are Sword Health Inc., Biofourmis Inc., Hinge Health Inc., Omada Health Inc., Evolv Rehabilitation Technologies Ltd., Click Therapeutics Inc., DarioHealth Corp., WellDoc Inc., Lark Technologies Inc., Kaia Health Software GmbH, Liva Healthcare A/S, Zibrio Inc., Gait Up SA, Noraxon Inc., Mira Rehab Limited, Cometa Srl., Koneksa Health Inc., Physitrack PLC, Kaia Health Inc., XRHealth USA Inc., MedRhythms Inc.

Get The Full Digital Therapeutics Sarcopenia Market Report:

https://www.thebusinessresearchcompany.com/report/digital-therapeutics-sarcopenia-global-market-report

Which Region Leads The Digital Therapeutics Sarcopenia Market In Overall Market Size?

North America was the largest region in the digital therapeutics sarcopenia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the digital therapeutics sarcopenia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Digital Therapeutics Sarcopenia Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/digital-therapeutics-sarcopenia-global-market-report

Browse Through More Reports Similar to the Global Digital Therapeutics Sarcopenia Market 2026, By The Business Research Company

Battery Separators Market Report 2026

https://www.thebusinessresearchcompany.com/report/battery-separators-global-market-report

Cutter Stapler Market Report 2026

https://www.thebusinessresearchcompany.com/report/cutter-stapler-global-market-report

Battery Manufacturing Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/battery-manufacturing-equipment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Estimated Market Size Of The Digital Therapeutics Sarcopenia Market In 2026, And How Will Its Value Evolve By 2030?

The digital therapeutics sarcopenia market size has seen rapid expansion in recent years. It is anticipated to increase from $1.54 billion in 2025 to $1.78 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 16.1%. The growth observed historically can be ascribed to elements such as the increasing prevalence of an aging population, heightened awareness of health risks linked to sarcopenia, the expansion of telehealth adoption, increasing acceptance of software-based medical therapies, and the early clinical validation of digital interventions.

The digital therapeutics sarcopenia market size is projected to experience substantial expansion in the coming years. This market is anticipated to reach a valuation of $3.21 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 15.9%. This projected growth throughout the forecast period stems from factors such as the heightened demand for home-based care for chronic conditions, the escalating incorporation of AI-powered personalized therapies, broadened reimbursement avenues for digital therapeutics, the expanding uptake of remote patient monitoring, and a reinforced emphasis on solutions for preventive muscle health. Key trends anticipated during this period encompass the wider acceptance of tailored digital therapy programs, the increased utilization of wearable devices for muscle monitoring, the broader implementation of remote physiotherapy platforms, the development of data-informed sarcopenia management strategies, and a stronger commitment to patient involvement and compliance.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/digital-therapeutics-sarcopenia-global-market-report

What Major Factors Are Driving The Digital Therapeutics Sarcopenia Market Forward?

The expanding presence of comorbidities is anticipated to fuel the expansion of the digital therapeutics sarcopenia market. Comorbidities are defined as the concurrent existence of multiple health conditions within a single individual. The increase in comorbidities stems from an aging demographic, as older age raises the probability of developing several chronic ailments due to diminishing physiological functions and extended exposure to various health hazards. Digital therapeutics designed for sarcopenia offer advantages in averting comorbidities, particularly obesity, by fostering consistent physical activity and muscle reinforcement, which aids in enhancing metabolism and minimizing fat accumulation. For example, data from March 2024, provided by the World Obesity Federation, a membership body based in the UK, projects that nearly 79% of adults impacted by overweight and obesity will reside in low- and middle-income nations by 2035, with the total count of obese adults forecast to reach 1.53 billion. Consequently, the increasing incidence of comorbidities is propelling the growth of the digital therapeutics sarcopenia market.

How Are Segments Identified Within The Digital Therapeutics Sarcopenia Market Segment Framework?

The digital therapeutics sarcopenia market covered in this report is segmented –

1) By Product: Software, Devices, Services

2) By Distribution Channel: Online Platforms, Direct-To-Consumer Digital Channels, Other Distribution Channels

3) By Application: Muscle Strengthening, Physical Activity Monitoring, Nutrition Management, Other Applications

4) By End User: Hospitals And Clinics, Homecare Settings, Rehabilitation Centers, Other End Users

Subsegments:

1) By Software: Mobile Applications, Web-Based Platforms, AI-Powered Monitoring Tools, Exercise And Rehabilitation Programs, Nutritional Guidance Software

2) By Devices: Wearable Fitness Trackers, Smart Scales, Connected Resistance Bands, Electromyography (EMG) Devices, Muscle Strength Assessment Tools

3) By Services: Remote Patient Monitoring Services, Virtual Physiotherapy Sessions, Teleconsultation Services, Personalized Coaching Services, Data Analytics And Reporting Services

Which Trends Are Impacting The Progress Of The Digital Therapeutics Sarcopenia Market?

Leading companies in the digital therapeutics sarcopenia market are concentrating on developing sophisticated solutions, such as drug discovery platforms. Their objective is to create more targeted therapies, improve treatment effectiveness, and accelerate the provision of personalized care for age-related muscle loss. A drug discovery platform aids in the quicker and more effective identification and creation of new drugs through advanced tools and methods. For example, in April 2025, ProFuse Technology, an Israel-based biotechnology company, unveiled a new drug discovery platform aimed at preventing muscle loss induced by GLP-1 weight-loss drugs, aging (sarcopenia), and cancer cachexia. By employing lab-grown, highly mature muscle tissues that accurately imitate natural muscle, the company can precisely test and screen drug candidates with enhanced speed and efficiency. This advanced platform reduces the dependence on animal testing and decreases research expenses. As the demand for muscle-preserving therapies rises, ProFuse is broadening its scope beyond cultivated meat into the biopharmaceutical industry, offering a pioneering strategy to address increasingly complex muscle health issues.

Who Are The Companies Competing Within The Digital Therapeutics Sarcopenia Market?

Major companies operating in the digital therapeutics sarcopenia market are Sword Health Inc., Biofourmis Inc., Hinge Health Inc., Omada Health Inc., Evolv Rehabilitation Technologies Ltd., Click Therapeutics Inc., DarioHealth Corp., WellDoc Inc., Lark Technologies Inc., Kaia Health Software GmbH, Liva Healthcare A/S, Zibrio Inc., Gait Up SA, Noraxon Inc., Mira Rehab Limited, Cometa Srl., Koneksa Health Inc., Physitrack PLC, Kaia Health Inc., XRHealth USA Inc., MedRhythms Inc.

Get The Full Digital Therapeutics Sarcopenia Market Report:

https://www.thebusinessresearchcompany.com/report/digital-therapeutics-sarcopenia-global-market-report

Which Region Leads The Digital Therapeutics Sarcopenia Market In Overall Market Size?

North America was the largest region in the digital therapeutics sarcopenia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the digital therapeutics sarcopenia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Digital Therapeutics Sarcopenia Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/digital-therapeutics-sarcopenia-global-market-report

Browse Through More Reports Similar to the Global Digital Therapeutics Sarcopenia Market 2026, By The Business Research Company

Battery Separators Market Report 2026

https://www.thebusinessresearchcompany.com/report/battery-separators-global-market-report

Cutter Stapler Market Report 2026

https://www.thebusinessresearchcompany.com/report/cutter-stapler-global-market-report

Battery Manufacturing Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/battery-manufacturing-equipment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Much Is The Digital Therapeutics Sarcopenia Market Expected To Grow In Terms Of Market Value Between 2026 And 2030?

The digital therapeutics sarcopenia market size has experienced rapid growth in recent years. It is projected to expand from $1.54 billion in 2025 to $1.78 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 16.1%. This historical growth can be ascribed to factors such as the rising prevalence of the aging population, increased awareness regarding sarcopenia-related health risks, the expansion of telehealth adoption, growing acceptance of software-based medical therapies, and the early clinical validation of digital interventions.

The digital therapeutics sarcopenia market size is projected to experience substantial growth in the upcoming years, with an expectation to reach $3.21 billion by 2030, advancing at a compound annual growth rate (CAGR) of 15.9%. This anticipated growth is primarily driven by factors such as the increasing demand for home-based chronic condition management, the rising integration of AI-driven therapeutic personalization, the expansion of reimbursement support for digital therapeutics, the growing adoption of remote patient monitoring, and an increasing focus on preventive muscle health solutions. Major trends anticipated in this forecast period include the increasing adoption of personalized digital therapy programs, the rising use of wearable-integrated muscle monitoring, the growing deployment of remote physiotherapy platforms, the expansion of data-driven sarcopenia management solutions, and an enhanced focus on patient engagement and adherence.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27278&type=smp

What Major Drivers Are Influencing Demand In The Digital Therapeutics Sarcopenia Market?

The increasing incidence of comorbidities is anticipated to drive the expansion of the digital therapeutics sarcopenia market. Comorbidities are defined as the concurrent presence of two or more health issues within an individual. This rise in comorbidities is linked to an aging demographic, where older age naturally leads to a greater chance of developing several chronic conditions because of deteriorating bodily functions and prolonged exposure to health hazards. Digital therapeutics designed for sarcopenia offer advantages in averting comorbidities, particularly obesity, through encouraging consistent physical activity and muscle building, which in turn boosts metabolism and diminishes fat buildup. As an illustration, the World Obesity Federation, a UK-based membership organization, reported in March 2024 that by 2035, close to 79% of adults experiencing overweight and obesity are projected to reside in low- and middle-income countries, with the total count of obese adults estimated to reach 1.53 billion. Consequently, the growing frequency of comorbidities is fueling the expansion of the digital therapeutics sarcopenia market.

What Major Segment Divisions Exist Within The Digital Therapeutics Sarcopenia Market?

The digital therapeutics sarcopenia market covered in this report is segmented –

1) By Product: Software, Devices, Services

2) By Distribution Channel: Online Platforms, Direct-To-Consumer Digital Channels, Other Distribution Channels

3) By Application: Muscle Strengthening, Physical Activity Monitoring, Nutrition Management, Other Applications

4) By End User: Hospitals And Clinics, Homecare Settings, Rehabilitation Centers, Other End Users

Subsegments:

1) By Software: Mobile Applications, Web-Based Platforms, AI-Powered Monitoring Tools, Exercise And Rehabilitation Programs, Nutritional Guidance Software

2) By Devices: Wearable Fitness Trackers, Smart Scales, Connected Resistance Bands, Electromyography (EMG) Devices, Muscle Strength Assessment Tools

3) By Services: Remote Patient Monitoring Services, Virtual Physiotherapy Sessions, Teleconsultation Services, Personalized Coaching Services, Data Analytics And Reporting Services

What Major Market Trends Are Driving Changes In The Digital Therapeutics Sarcopenia Market?

Key players within the digital therapeutics sarcopenia market are concentrating on advancing solutions, particularly drug discovery platforms, to formulate more precise therapies, improve treatment efficacy, and speed up the provision of tailored care for muscle loss associated with aging. A drug discovery platform aids in the quicker and more effective identification and creation of new medications by utilizing advanced instruments and techniques. For example, in April 2025, ProFuse Technology, an Israel-based biotechnology enterprise, introduced a new drug discovery platform specifically targeting the prevention of muscle loss induced by GLP-1 weight-loss drugs, aging (sarcopenia), and cancer cachexia. By employing lab-cultivated, highly mature muscle tissues that emulate natural muscle, the company is able to accurately test and screen drug candidates with greater speed and efficiency. This sophisticated platform diminishes reliance on animal testing and reduces research expenditures. As therapies aimed at preserving muscle become more sought after, ProFuse is expanding its focus beyond cultivated meat into biopharma, providing an innovative strategy to address the increasing challenges related to muscle health.

Which Companies Are Leading Innovation In The Digital Therapeutics Sarcopenia Market?

Major companies operating in the digital therapeutics sarcopenia market are Sword Health Inc., Biofourmis Inc., Hinge Health Inc., Omada Health Inc., Evolv Rehabilitation Technologies Ltd., Click Therapeutics Inc., DarioHealth Corp., WellDoc Inc., Lark Technologies Inc., Kaia Health Software GmbH, Liva Healthcare A/S, Zibrio Inc., Gait Up SA, Noraxon Inc., Mira Rehab Limited, Cometa Srl., Koneksa Health Inc., Physitrack PLC, Kaia Health Inc., XRHealth USA Inc., MedRhythms Inc.

Read the full digital therapeutics sarcopenia market report here:

https://www.thebusinessresearchcompany.com/report/digital-therapeutics-sarcopenia-global-market-report

Which Region Shows The Strongest Potential For Future Growth In The Digital Therapeutics Sarcopenia Market?

North America was the largest region in the digital therapeutics sarcopenia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the digital therapeutics sarcopenia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Digital Therapeutics Sarcopenia Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=27278&type=smp

Browse Through More Reports Similar to the Global Digital Therapeutics Sarcopenia Market 2026, By The Business Research Company

Cutter Stapler Global Market Report

https://www.thebusinessresearchcompany.com/report/cutter-stapler-global-market-report

Battery Manufacturing Equipment Global Market Report

https://www.thebusinessresearchcompany.com/report/battery-manufacturing-equipment-global-market-report

Battery Separators Global Market Report

https://www.thebusinessresearchcompany.com/report/battery-separators-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model